| HOME >> BIOLOGY >> TECHNOLOGY |
CASH FLOWS FROM OPERATING
ACTIVITIES:
Net income/(loss) 11.8 34.7 61.4 (1,663.9)
Adjustments to reconcile net
income/(loss) to net cash provided
by operating activities:
Loss from discontinued operations 0.9 - 0.9 -
Depreciation and amortization 49.1 48.1 145.4 111.8
Amortization of deferred financing
charges 1.3 1.4 3.8 10.6
Interest on building financing
obligation 0.7 - 2.6 -
Impairment of intangible assets - - 90.4 -
Impairment of available of sale
securities 54.1 - 54.1 -
Share based compensation 16.2 11.7 52.0 34.1
In-process R&D charge 120.5 - 120.5 1,896.0
Gain on sale of product rights (4.0) (7.1) (20.7) (12.1)
Gain on sale of long-term assets 0.4 - (9.4) -
Movement in deferred taxes 6.8 (49.6) 24.2 (35.8)
Equity in earnings of equity
method investees (1.6) (0.5) (1.3) (1.7)
Minority Interest (1.3) - (1.3) -
Changes in operating assets and
liabilities, net of acquisitions:
(Increase)/decrease in accounts
receivable (12.3) 38.8 (40.7) (64.2)
Increase in sales deduction
accrual 1.4 0.4 36.9 19.3
Decrease/(increase) in inventory 29.2 (6.2) 39.6 (46.2)
(Increase)/decrease in prepayments
and other current assets (8.4) (8.6) 15.8 2.7
(Incre
'/>"/>
| SOURCE Shire Plc Copyright©2008 PR Newswire. All rights reserved |